Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina V. Long(The University of Sydney), Uwe Trefzer(Charité - Universitätsmedizin Berlin), Michael A. Davies(The University of Texas MD Anderson Cancer Center), Richard Kefford(The University of Sydney), Paolo A. Ascierto(Fondazione IRCCS Istituto Nazionale dei Tumori), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Igor Puzanov(Vanderbilt University), Axel Hauschild(University Hospital Schleswig-Holstein), Caroline Robert(Inserm), Alain P. Algazi(University of California, San Francisco), Laurent Mortier(Centre Hospitalier Universitaire de Lille), Hussein A. Tawbi(University of Pittsburgh), Tabea Wilhelm(Charité - Universitätsmedizin Berlin), Lisa Zimmer(Essen University Hospital), Julie Switzky(GlaxoSmithKline (United States)), S. Swann(GlaxoSmithKline (United States)), Anne-Marie Martin(GlaxoSmithKline (United States)), Mary Guckert(GlaxoSmithKline (United States)), Vicki Goodman(GlaxoSmithKline (United States)), Michael Streit(GlaxoSmithKline (United States)), John M. Kirkwood(University of Pittsburgh), Dirk Schadendorf(Essen University Hospital)
Cited by 905
Abstract
Related Papers
No related papers found
Powered by citation graph analysis